Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + carboplatin/etoposide induction followed by adebrelimab + fluzoparib maintenance in extensive-stage small cell lung cancer
ChiCTR2300070028Phase 2Not yet recruiting
- Sponsor
- The Third Medical Center of the Chinese People's Liberation Army General Hospital
- Start
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and fluzoparib in small cell lung cancer (SCLC), sponsored by The Third Medical Center of the Chinese People's Liberation Army General Hospital. Primary endpoint: Investigator-assessed 6-month progression-free survival rate. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
adebrelimabfluzoparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2300070028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070028.